Tacrolimus
Who holds supplier records for Tacrolimus? 19 organisations hold a current record for Tacrolimus: an active US FDA Type II Drug Master File or a CEP. A further 3 organisations have only historical (inactive) DMF filings. 10 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: China (6), India (4), Slovenia (1), Netherlands (1) and 4 other countries (4); not recorded for 3.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Tacrolimus: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/tacrolimus
Reading the evidence
- 19 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 6 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Tacrolimus expires 30 Aug 2028. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (19)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Tacrolimus. Country is the organisation's recorded country, not necessarily the manufacturing site.
- Biocon LimitedIndiaCEPActive DMF 39573, 18442, 23365 · latest filing Mar 2024
- CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTDCEP Company GMP cert on recordActive DMF 18985, 38310 · latest filing Apr 2023
- CONCORD BIOTECH LTDIndiaCEP Company GMP cert on recordActive DMF 18908, 34491 · latest filing Jan 2020
- Lek Pharmaceuticals D.D.SloveniaCEP Company GMP cert on recordActive DMF 19979, 34063 · latest filing Aug 2020
- HISUN PHARMACEUTICAL HANGZHOU CO LTDCEPActive DMF 27202 · latest filing Jun 2013
- JOYANG LABORATORIESChinaCEPActive DMF 31225, 34630 · latest filing Mar 2020
- NORTH CHINA PHARMACEUTICAL HUASHENG CO LTDChinaCEP Company GMP cert on recordActive DMF 34270 · latest filing Mar 2020
- TAPI NL BVNetherlandsCEPActive DMF 28524 · latest filing Aug 2014
- Wuxi Fortune Pharmaceutical Co., Ltd.ChinaCEP Company GMP cert on recordActive DMF 39816 · latest filing Jun 2024
- Apotex Inc.CanadaActive DMF 28065 · latest filing Mar 2014
- Astellas Pharma Inc.Japan Company GMP cert on recordActive DMF 16833 · latest filing Sept 2003
- CHENGDU YACHT BIO-TECHNOLOGY CO LTDChinaActive DMF 40448 · latest filing Oct 2024
- CKD BIO CORPSouthActive DMF 31097 · latest filing Oct 2016
- FARMHISPANIA SASpainActive DMF 35852 · latest filing Apr 2021
- FISHFA BIOGENICS (A DIV OF FISHFA RUBBERS LTD)IndiaActive DMF 39667, 41828 · latest filing Jun 2025
- FUJIAN KERUI PHARMACEUTICAL CO LTDChinaActive DMF 21808 · latest filing Jul 2008
- Guangdong Blue Treasure Pharmaceuticals Co. Ltd.ChinaActive DMF 44366 · latest filing Jun 2026
- LUNAN NEW TIME BIO-TECH CO LTDActive DMF 37982, 38985 · latest filing Nov 2023
- Fishfa BiogenicsIndiaCEP
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Valid CEP holder entries (10)
Certificates of Suitability on the EDQM register for Tacrolimus, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 12 certificates in total, including withdrawn, expired, suspended and repeat certificates.
| Holder | Country | Certificate | Issued | EU GMP at holder's address |
|---|---|---|---|---|
| TAPI NL B.V. Amsterdam | NL | CEP 2018-233 - Rev 07 Tacrolimus monohydrate | Apr 2026 | — |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. Shu Lin | TW | CEP 2018-241 - Rev 03 Tacrolimus monohydrate | Feb 2026 | Inspected Apr 2024 Germany |
| FISHFA BIOGENICS Rajkot | IN | CEP 2023-394 - Rev 00 Tacrolimus monohydrate | Sept 2025 | — |
| CONCORD BIOTECH LIMITED Ahmedabad | IN | CEP 2020-227 - Rev 02 Tacrolimus monohydrate, Process II | Jul 2025 | Inspected Jul 2025 Germany |
| BIOCON LIMITED Bengaluru | IN | CEP 2017-257 - Rev 02 Tacrolimus monohydrate | Jun 2025 | — |
| HISUN PHARMACEUTICAL (HANGZHOU) CO., LTD. Hangzhou City | CN | CEP 2018-284 - Rev 02 Tacrolimus monohydrate | Oct 2024 | — |
| WUXI FORTUNE PHARMACEUTICAL CO., LTD. Wuxi | CN | CEP 2023-051 - Rev 00 Tacrolimus monohydrate | Sept 2024 | Inspected Mar 2025 Germany |
| JOYANG LABORATORIES Yancheng | CN | CEP 2021-210 - Rev 01 Tacrolimus monohydrate | Jul 2024 | Inspected Nov 2024 Germany |
| LEK PHARMACEUTICALS D.D. Ljubljana | SI | R0-CEP 2021-204 - Rev 01 Tacrolimus monohydrate | Aug 2023 | — |
| North China Pharmaceutical Huasheng Co., Ltd. Shijiazhuang | CN | R0-CEP 2021-180 - Rev 01 Tacrolimus monohydrate | Jun 2023 | — |
The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.
Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.
Historical records (3)
Organisations whose Type II DMFs for Tacrolimus are no longer active. These show a past filing, not current supply.
Show all 3 historical records
- Brazil · Inactive DMF 22254 · filed Nov 2008
- HANGZHOU HUADONG MEDICINE GROUP BIOTECHNOLOGY INSTITUTE CO LTDInactive DMF 20390 · filed Mar 2007
- China · Inactive DMF 19072 · filed Dec 2005
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (58 listed products contain Tacrolimus). The latest listed patent expires 30 Aug 2028. The latest listed exclusivity runs to 16 Jul 2028. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Tacrolimus is an immunosuppressive drug primarily used to reduce the risk of organ transplant rejection. It acts by inhibiting T-lymphocyte activation.
Chemical identity
- IUPAC name
- (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-prop-2-enyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone;hydrate
- Canonical SMILES
- C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC.O
- InChIKey
- NWJQLQGQZSIBAF-MLAUYUEBSA-N
- Synonyms
- Protopic API, advagraf, envarsus xr, fk-506, fk506, fr-900506, fr900506, modigraf, nsc-758659, prograf, protopic, tacrolimus hydrate
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Calcineurin Inhibitor Immunosuppressant
- Mechanism of action
- Calcineurin Inhibitors
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Tacrolimus?
19 organisations hold an active US FDA Type II Drug Master File or a CEP for Tacrolimus: Biocon Limited (India), CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD, CONCORD BIOTECH LTD (India), Lek Pharmaceuticals D.D. (Slovenia), HISUN PHARMACEUTICAL HANGZHOU CO LTD, JOYANG LABORATORIES (China), NORTH CHINA PHARMACEUTICAL HUASHENG CO LTD (China) and TAPI NL BV (Netherlands), and 11 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Tacrolimus Drug Master Files are active?
Biocon Limited (DMF 39573, 18442), CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD (DMF 18985, 38310), CONCORD BIOTECH LTD (DMF 18908, 34491), Lek Pharmaceuticals D.D. (DMF 19979, 34063), HISUN PHARMACEUTICAL HANGZHOU CO LTD (DMF 27202), JOYANG LABORATORIES (DMF 31225, 34630), NORTH CHINA PHARMACEUTICAL HUASHENG CO LTD (DMF 34270) and TAPI NL BV (DMF 28524) and 10 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Tacrolimus records mean?
3 organisations have only inactive Type II DMFs for Tacrolimus. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does Tacrolimus have a European Certificate of Suitability?
Yes. 10 organisations hold a valid CEP for Tacrolimus on the EDQM register, including TAPI NL B.V. Amsterdam (NL), Chunghwa Chemical Synthesis & Biotech Co., Ltd. Shu Lin (TW), FISHFA BIOGENICS Rajkot (IN), CONCORD BIOTECH LIMITED Ahmedabad (IN), BIOCON LIMITED Bengaluru (IN) and HISUN PHARMACEUTICAL (HANGZHOU) CO., LTD. Hangzhou City (CN) and 4 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
Does the FDA Orange Book list patents for products containing Tacrolimus?
Yes. The latest patent listed for an approved US product containing Tacrolimus expires 30 Aug 2028, across 58 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Tacrolimus supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Tacrolimus?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.